Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Aralez Pharmaceuticals Inc. (ARLZ) since 2016 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Aralez Pharmaceuticals Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1660719.
Total stock buying since 2016: $4,140,860.
Total stock sales since 2016: $17,448,395.
Total stock option exercises since 2016: $541,927.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2018 | 0 | $0 | 204,770 | $113,001 | 0 | $0 |
| 2017 | 704,750 | $1,590,021 | 592,105 | $846,088 | 0 | $0 |
| 2016 | 516,429 | $2,550,839 | 2,674,778 | $16,489,306 | 137,286 | $541,927 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2018-06 | 0 | $0 | 156,573 | $58,558 | 0 | $0 |
| 2018-05 | 0 | $0 | 23,312 | $12,140 | 0 | $0 |
| 2018-03 | 0 | $0 | 24,885 | $42,303 | 0 | $0 |
| 2017-12 | 50,000 | $73,550 | 0 | $0 | 0 | $0 |
| 2017-10 | 0 | $0 | 9,960 | $24,919 | 0 | $0 |
| 2017-07 | 0 | $0 | 10,804 | $13,505 | 0 | $0 |
| 2017-06 | 65,000 | $75,725 | 169,626 | $217,344 | 0 | $0 |
| 2017-05 | 0 | $0 | 388,685 | $558,918 | 0 | $0 |
| 2017-03 | 589,750 | $1,440,746 | 13,030 | $31,402 | 0 | $0 |
| 2016-11 | 31,000 | $148,080 | 124,778 | $616,156 | 124,778 | $489,129 |
| 2016-09 | 295,929 | $1,732,664 | 150,000 | $873,150 | 0 | $0 |
| 2016-06 | 0 | $0 | 0 | $0 | 4,365 | $12,309 |
| 2016-05 | 189,500 | $670,095 | 0 | $0 | 0 | $0 |
| 2016-03 | 0 | $0 | 2,400,000 | $15,000,000 | 0 | $0 |
| 2016-02 | 0 | $0 | 0 | $0 | 8,143 | $40,489 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2018-06-04 | Koven Andrew I (President & Chief Business Officer) | Sale | 156,573 | .37 | 58,558 |
| 2018-05-14 | Tursi James Patrick (Chief Medical Officer) | Sale | 9,348 | .52 | 4,879 |
| 2018-05-14 | Koven Andrew I (President & Chief Business Officer) | Sale | 13,964 | .52 | 7,261 |
| 2018-03-19 | Trachtenberg Eric (GC, CCO & Secretary) | Sale | 3,471 | 1.70 | 5,900 |
| 2018-03-19 | Tursi James Patrick (Chief Medical Officer) | Sale | 5,950 | 1.70 | 10,115 |
| 2018-03-19 | Glickman Mark A (Chief Commercial Officer) | Sale | 5,725 | 1.70 | 9,732 |
| 2018-03-19 | Koven Andrew I (President & Chief Business Officer) | Sale | 9,739 | 1.70 | 16,556 |
| 2017-12-08 | Kirsch Arthur S (Director) | Buy | 50,000 | 1.47 | 73,550 |
| 2017-10-02 | Tursi James Patrick (Chief Medical Officer) | Sale | 9,960 | 2.50 | 24,919 |
| 2017-07-28 | Charles Scott J (Chief Financial Officer) | Sale | 10,804 | 1.25 | 13,505 |
| 2017-06-23 | Trachtenberg Eric (GC, CCO & Secretary) | Sale | 7,720 | 1.33 | 10,267 |
| 2017-06-15 | Kirsch Arthur S (Director) | Buy | 15,000 | 1.15 | 17,175 |
| 2017-06-14 | Kirsch Arthur S (Director) | Buy | 50,000 | 1.17 | 58,550 |
| 2017-06-05 | Koven Andrew I (President & Chief Business Officer) | Sale | 161,906 | 1.28 | 207,077 |
| 2017-05-23 | Aryeh Jason (Director) | Sale | 104,176 | 1.41 | 146,888 |
| 2017-05-22 | Aryeh Jason (Director) | Sale | 233,468 | 1.42 | 332,458 |
| 2017-05-19 | Aryeh Jason (Director) | Sale | 51,041 | 1.56 | 79,572 |
| 2017-03-20 | Charles Scott J (Chief Financial Officer) | Sale | 5,205 | 2.41 | 12,544 |
| 2017-03-20 | Koven Andrew I (President & Chief Business Officer) | Sale | 7,825 | 2.41 | 18,858 |
| 2017-03-15 | Tursi James Patrick (Chief Medical Officer) | Buy | 4,750 | 2.11 | 10,022 |
| 2017-03-15 | Kirsch Arthur S (Director) | Buy | 45,000 | 2.27 | 102,239 |
| 2017-03-15 | Koven Andrew I (President & Chief Business Officer) | Buy | 20,000 | 2.55 | 50,920 |
| 2017-03-15 | Adams Adrian (Chief Executive Officer) | Buy | 500,000 | 2.46 | 1,231,000 |
| 2017-03-15 | Lee Kenneth B Jr (Director) | Buy | 5,000 | 2.52 | 12,620 |
| 2017-03-15 | Rudnick Seth (Director) | Buy | 15,000 | 2.26 | 33,945 |
| 2016-11-29 | Harris Robert Paul (Director) | Sale | 104,778 | 4.99 | 523,156 |
| 2016-11-29 | Harris Robert Paul (Director) | Option Ex | 104,778 | 3.92 | 410,729 |
| 2016-11-28 | Harris Robert Paul (Director) | Sale | 20,000 | 4.65 | 93,000 |
| 2016-11-28 | Harris Robert Paul (Director) | Option Ex | 20,000 | 3.92 | 78,400 |
| 2016-11-14 | Lee Kenneth B Jr (Director) | Buy | 1,000 | 4.95 | 4,950 |
| 2016-11-11 | Rudnick Seth (Director) | Buy | 30,000 | 4.77 | 143,130 |
| 2016-09-16 | Aryeh Jason (Director) | Buy | 295,929 | 5.86 | 1,732,664 |
| 2016-09-15 | Harris Robert Paul (Director) | Sale | 150,000 | 5.82 | 873,150 |
| 2016-06-13 | Thrasher Francis Martin (Director) | Option Ex | 4,365 | 2.82 | 12,309 |
| 2016-05-16 | Trachtenberg Eric (GC, CCO & Secretary) | Buy | 10,000 | 3.76 | 37,570 |
| 2016-05-16 | Tursi James Patrick (Chief Medical Officer) | Buy | 4,500 | 3.79 | 17,037 |
| 2016-05-16 | Glickman Mark A (Chief Commercial Officer) | Buy | 25,000 | 3.68 | 92,050 |
| 2016-05-13 | Lee Kenneth B Jr (Director) | Buy | 1,000 | 3.50 | 3,500 |
| 2016-05-12 | Charles Scott J (Chief Financial Officer) | Buy | 50,000 | 3.49 | 174,500 |
| 2016-05-12 | Kirsch Arthur S (Director) | Buy | 27,500 | 3.49 | 95,975 |
| 2016-05-12 | Koven Andrew I (President & Chief Business Officer) | Buy | 71,500 | 3.49 | 249,463 |
| 2016-03-17 | Qlt Inc/bc (10% Owner) | Sale | 2,400,000 | 6.25 | 15,000,000 |
| 2016-02-05 | Kirsch Arthur S (Director) | Option Ex | 6,107 | 5.97 | 36,458 |
| 2016-02-04 | Barnhardt John E (VP, Finance & Administration) | Option Ex | 2,036 | 1.98 | 4,031 |
Insider trading activities including stock purchases, stock sales, and option exercises of ARLZ listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Aralez Pharmaceuticals Inc. (symbol ARLZ, CIK number 1660719) see the Securities and Exchange Commission (SEC) website.